Compare TK & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | LBRX |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | 27 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 942.3M | 958.7M |
| IPO Year | 1995 | N/A |
| Metric | TK | LBRX |
|---|---|---|
| Price | $10.64 | $31.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | ★ 553.1K | 351.9K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $13.40 |
| 52 Week High | $14.38 | $35.35 |
| Indicator | TK | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 49.89 |
| Support Level | $9.63 | $26.75 |
| Resistance Level | $12.50 | $34.10 |
| Average True Range (ATR) | 0.39 | 1.98 |
| MACD | 0.07 | -0.30 |
| Stochastic Oscillator | 58.74 | 34.42 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.